American Society of Hematology Annual Meeting & Exposition (ASH)

More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.

Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.

NFKB1 rs230511 genetic variant improves treatment outcomes for patients with polycythemia vera and essential thrombocythemia.

Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.

The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.

Navtemadlin shows influence in myelofibrosis hallmarks such as CD34-positive cell proliferation and pro-inflammatory cytokines in the phase 3 BOREAS trial.

Data from the phase 3 ASC4FIRST trial support asciminib as a standard of care in newly diagnosed chronic myeloid leukemia in chronic phase.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

Data from a phase 1 study support further analysis of BGB-16673 across several B-cell malignancies, according to the study investigators.

Data from the phase 1/2 MonumenTAL-1 studies support flexibility to adjusting the dose of talquetamab in patients with relapsed/refractory multiple myeloma who already have a response.

Because patients with myeloma are at a high risk for financial hardship, study findings support the use of a financial navigation program to reduce financial toxicities of patients.

Treatment with NX-2127 leads to clinically meaningful activity in heavily pretreated chronic lymphocytic leukemia, according to results from the phase 1 NX-2127-001 trial.

Investigators of a phase 1 trial identify no safety signals with Orca-Q in the haploidentical stem cell transplantation setting.

Investigators report that response-adapted trials utilizing novel combination regimens appear to be safe and feasible in a population of patients with newly diagnosed diffuse large B-cell lymphoma.

The combination of pelabresib plus ruxolitinib shows improvement in hemoglobin response in the MANIFEST-2 trial, supporting a potential shift in the future treatment of patients with JAK inhibitor–naive myelofibrosis.

Treatment with zanubrutinib may be a viable option for patients with B-cell malignancies who are intolerant to acalabrutinib, says Mazyar Shadman, MD.

Treatment with CAR T cells may allow patients with hematologic malignancies to recover more quickly compared with a transplant, says Andre Goy, MD.

Treatment with ruxolitinib improves the probability of failure-free survival compared with best available treatment among those with chronic graft-versus-host-disease in the phase 3 REACH3 study.

Data from the phase 3 APPLY-PNH trial show comprehensive control of intravascular and extravascular hemolysis with iptacopan in patients with paroxysmal nocturnal hemoglobinuria and persistent anemia.

Phase 2 results showed that the investigational monoclonal antibody axatilimab elicited encouraging clinical activity and tolerability across dose levels in patients with recurrent or refractory chronic graft-vs-host disease.

Retrospective, real-world results showed that oral decitabine and cedazuridine and standard parenteral hypomethylating agents demonstrated similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

Single-agent treatment with odronextamab continued to demonstrate encouraging clinical activity, along with a manageable safety profile, in patients with relapsed/refractory diffuse large B-cell lymphoma.

When used as a minimal residual disease (MRD)–guided treatment approach, ibrutinib (Imbruvica) combined with venetoclax (Venclexta) improved progression-free and overall survival (OS) compared with fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) in patients with treatment-naive chronic lymphocytic leukemia (CLL), as observed in the phase 3 FLAIR trial.

Dose reductions and interruptions of navitoclax plus ruxolitinib in the TRANSFORM-1 trial appear to be mostly due to thrombocytopenia, according to Naveen Pemmaraju, MD.

Older patients with hematological malignancies who received Orca-T therapy plus myeloablative chemotherapy have similar relapse-free survival rates compared with younger patients.

No patients with myelodysplastic syndrome have any grade 3 or higher acute graft-versus-host disease following treatment with Orca-T in a phase 1b study.

A virtual care platform significantly reduces hospital days for patients who are receiving CAR T-cell therapy, says Tonya Cox, BSN, RN, OCN.

An AI algorithm was created to distinguish prefibrotic primary myelofibrosis and essential thrombocythemia from each other.

In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.

Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center.